Anirban Maitra: Preclinical data on potential combination to overcome KRASi resistance
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X, about a recent paper by Bruna Pellini et al. published in bioRxiv.
“New preprint of preclinical data from Bruna Pellini, Moffitt Cancer Center on potential combination to overcome KRASi resistance.
Trastuzumab deruxtecan combination strongly enhances responses and overcomes sotorasib resistance in KRASG12C-mutant NSCLC.
Importantly, the Sotorasib-Enhertu combination efficacy Lung Cancer models tracks with the levels of HER-2 expression.
An important message for pathologists discussed in this preprint pertains to the varying schema (breast cancer versus upper GI) for assessing HER-2 expression in NSCLC and the need for standardization.”
Authors: Hilal Ozakinci, Bina Desai, Denise Kalos, Andriy Marusyk, Bruna Pellini et al.
More posts featuring Anirban Maitra.
Dr. Anirban Maitra serves as a Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center.
He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
Bruna Pellini is an Assistant Professor at the University of South Florida and an Assistant Member in the Department of Thoracic Oncology at Moffitt Cancer Center. Her research centers on the use of liquid biopsies to monitor treatment response, detect minimal residual disease (MRD), and integrate these techniques into clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023